Association of urinary albumin to creatinine ratio with different gender, age and clinical characteristics in patients with STEMI

Main Article Content

A. V. Bronyk
V. P. Ivanov
L. V. Rasputina


The work method revealed the clinical course of STEMI depending on the functional state of the kidneys and ACR in the urine. Included were 286 patients with acute coronary syndromes, average age 62.8±9.8 years, after revascularization. Among the examined were 202 (70.6%) men and 84 (29.4%) women. It was established that 158 ​​places were classified as ACR <3, 92 individuals – ACR 3–30 mg/mmol and 36 – ACR >30 mg/mmol. Gender characteristics show that women were significantly more likely to belong to the group of ACR >30 mg/mmol, the distribution into different age gradations according to WHO (2015) showed that at the age of 25–44 all patients belonged to group 1 (ACR >3 mg/mmol ) and group 2 (ACR 3–30 mg/mmol). Among cases aged 75–89, there were significantly more persons with ACR >30 mg/mmol, p1–3=0.003; p2–3=0.01 the value of GFR calculated from the level of cystatin C in plasma according to the CKD-EPI formula Cystatin C shows significantly lower GFR in various categories of ACR based on GFR calculated on the basis of creatinine. With a decrease in GFR, the number of deficiencies that had gradations of ACR 3–30 and ACR >30 significantly increases. The clinical course of STEMI in the treatment of ACR over 30 is characterized by a longer history of hypertension and diabetes, a greater number of patients with diabetes, hereditary history of cardiovascular diseases, diagnosis of atrial fibrillation.

Article Details


acute myocardial infarction, acute coronary syndrome, revascularization, glomerular filtration rate, kidney function, creatinine, cystatin C, albumin/creatinine ratio in urine, cardiovascular diseases


Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285-95.

Borg R, Kriegbaum M, Grand MK, Lind B, Andersen CL, Persson F. Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death. BMC Prim Care. 2023;24(1):128. Published 2023 Jun 21.

Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, Matsushita K, Surapaneni A, Brunskill N, Chadban SJ, Chang AR, Cirillo M, Daratha KB, Gansevoort RT, Garg AX, Iacoviello L, Kayama T, Konta T, Kovesdy CP, Lash J, Lee BJ, Major RW, Metzger M, Miura K, Naimark DMJ, Nelson RG, Sawhney S, Stempniewicz N, Tang M, Townsend RR, Traynor JP, Valdivielso JM, Wetzels J, Polkinghorne KR, Heerspink HJL; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81.

Darlington O, Dickerson C, Evans M, McEwan P, Sörstadius E, Sugrue D, van Haalen H, Garcia Sanchez JJ. Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kid-ney Disease: Evidence from a Systematic Literature Review. Adv Ther. 2021;38(2):994-1010.

Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, Shardlow A, Taal MW. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study [published correction appears in BMC Nephrol. 2020 Dec 21;21(1):543]. BMC Nephrol. 2015;16:193. Published 2015 Dec 1.

Hu C, Li Y, Qian Y, Wu Z, Hu B, Peng Z. Kidney function and cardiovascular diseases: a large-scale observational and Mendelian randomization study. Front Immunol. 2023;14:1190938. Published 2023 Jul 17.

Matsushita K, Kaptoge S, Hageman SHJ, Sang Y, Ballew SH, Grams ME, Surapaneni A, Sun L, Arnlov J, Bozic M, Brenner H, Brunskill NJ, Chang AR, Chinnadurai R, Cirillo M, Correa A, Ebert N, Eckardt KU, Gansevoort RT, Gutierrez O, Hadaegh F, He J, Hwang SJ, Jafar TH, Jassal SK, Kayama T, Kovesdy CP, Landman GW, Levey AS, Lloyd-Jones DM, Major RW, Miura K, Muntner P, Nadkarni GN, Nowak C, Ohkubo T, Pena MJ, Polkinghorne KR, Sairenchi T, Schaeffner E, Schneider MP, Shalev V, Shlipak MG, Solbu MD, Stempniewicz N, Tollitt J, Valdivielso JM, van der Leeuw J, Wang AY, Wen CP, Woodward M, Yamagishi K, Yatsuya H, Zhang L, Dorresteijn JAN, Di Angelantonio E, Visseren FLJ, Pennells L, Coresh J. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Eur J Prev Cardiol. 2023;30(1):8-16.

Ortiz A, Wanner C, Gansevoort R; ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Clin Kidney J. 2022;16(3):403-7. Published 2022 Oct 11.

Ruiz-Garcia A, Arranz-Martínez E, Iturmendi-Martínez N, Fernández-Vicente T, Rivera-Teijido M, García-Álvarez JC. Prevalence rates of chronic kidney disease and its association with cardiometabolic factors and cardiovascular diseases. SIMETAP-CKD study. Tasas de prevalencia de enfer-medad renal crónica y su asociación con factores cardiometabólicos y enferme-dades cardiovasculares. Estudio SIMETAP-ERC. Clin Investig Arterioscler. 2023;35(2):64-74.

Szlagor M, Dybiec J, Młynarska E, Rysz J, Franczyk B. Chronic Kidney Disease as a Comorbid-ity in Heart Failure. Int J Mol Sci. 2023;24(3):2988. Published 2023 Feb 3.

Zhai YS, Cheng YJ, Deng HW, Li J, Peng L, Gao X. Associations of Renal Function Trajectories and Long-Term Cardiovascular Risks Among a Population Without Chronic Kidney Disease. J Am Heart Assoc. 2023;12(8):e028556.